These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25960345)

  • 1. Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
    Li L; Sagot B; Zhou FM
    Brain Res; 2015 Jul; 1615():12-21. PubMed ID: 25960345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperactive Response of Direct Pathway Striatal Projection Neurons to L-dopa and D1 Agonism in Freely Moving Parkinsonian Mice.
    Sagot B; Li L; Zhou FM
    Front Neural Circuits; 2018; 12():57. PubMed ID: 30104963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
    Wang Y; Bouabid S; Darvas M; Zhou FM
    Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.
    Bagga V; Dunnett SB; Fricker RA
    Behav Brain Res; 2015 Jul; 288():107-17. PubMed ID: 25841616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
    Ando K; Nishime C; Inoue R; Nishinaka E; Kawai K; Urano K; Tsutsumi H
    Behav Pharmacol; 2017 Dec; 28(8):670-680. PubMed ID: 29099404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
    Espadas I; Darmopil S; Vergaño-Vera E; Ortiz O; Oliva I; Vicario-Abejón C; Martín ED; Moratalla R
    Neurobiol Dis; 2012 Dec; 48(3):271-81. PubMed ID: 22820144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
    Wei W; Ding S; Zhou FM
    J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine.
    Mura A; Jackson D; Manley MS; Young SJ; Groves PM
    Brain Res; 1995 Dec; 704(1):51-60. PubMed ID: 8750961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
    Cenci MA; Tranberg A; Andersson M; Hilbertson A
    Neuroscience; 1999; 94(2):515-27. PubMed ID: 10579213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Zhang K; Chammas C; Soghomonian JJ
    Neuroscience; 2015 Sep; 303():586-94. PubMed ID: 26188284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
    Alcacer C; Charbonnier-Beaupel F; Corvol JC; Girault JA; Hervé D
    Neurosci Lett; 2014 Nov; 583():76-80. PubMed ID: 25233866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation.
    Wang Y; Zhou FM
    Front Pharmacol; 2017; 8():935. PubMed ID: 29311936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.